EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity

Patricia D Maglalang, Daniel Gonzalez iD, William J Muller iD, Chi D Hornik, Stuart L Goldstein iD, Mobeen Rathore iD, Jennifer L Ford, Stephen J Balevic iD, Jaydeep Sinha, Andrea Edginton iD, Rachel G Greenberg iD, Daniel K Benjamin und 3 weitere

The Journal of Clinical Pharmacology · 2026-10 · 66 (10)

DOI: 10.1002/jcph.70264 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Pharmacology, online erschienen am 29.09.2026. Verfasst von Patricia D Maglalang und 14 weiteren Autor:innen. Beteiligte Einrichtung: Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. Hauptthemen laut MEDLINE: Topiramate, Models, Biological, Anticonvulsants, Fructose. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Topiramate (TPM) is used to treat seizures in adults and children ≥2 years. In children, TPM dosing is body weight based. It is unknown whether children with obesity may benefit from an alternative dosing strategy. We developed a novel physiologically based pharmacokinetic (PBPK) model for TPM that accounts for age‐ and obesity‐related changes in disposition. The model was first developed and evaluated in adults before scaling to children then finally evaluated using opportunistic pharmacokinetic data from two multicenter studies where children with and without obesity ages 2–18 years received TPM per standard of care. Simulations were performed to characterize pharmacokinetic parameters and assess the current labeled dosing regimen in a virtual population of children with obesity (≥2 years). The adult PBPK model performed well when evaluated with observed literature data, resulting in an average fold error of 0.989 across the dosing range of 25–1200 mg. The pediatric data used in model evaluation included 43 children (86% with obesity; median [range], 8 [2–18] years); 71% of 134 observed concentrations fell within the 90% prediction interval for the PBPK model. PBPK based dosing simulations revealed comparable exposure (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TopiramateModels, BiologicalAnticonvulsantsFructosePediatric ObesityObesityHumansChildAdolescentChild, PreschoolMaleFemaleComputer Simulation

Stichwörter der Autor:innen

clinical pharmacologyobesitypediatricspharmacokineticstopiramate

Substanzen

TopiramateAnticonvulsantsFructose

Autor:innen und Institutionen

  • Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA.
  • Duke Clinical Research Institute, Durham, NC, USA.
  • Department of Medicine, Duke University School of Medicine, Durham, NC, USA.
  • Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
  • Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA.
  • Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.

ORCID-Profile: Daniel Gonzalez, William J Muller, Stuart L Goldstein, Mobeen Rathore, Stephen J Balevic, Andrea Edginton, Rachel G Greenberg, Kanecia O Zimmerman

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Maglalang, P. D., Gonzalez, D., Muller, W. J., Hornik, C. D., Goldstein, S. L., Rathore, M., Ford, J. L., Balevic, S. J., Sinha, J., Edginton, A., Greenberg, R. G., Benjamin, D. K., Chen, J. Y., Zimmerman, K. O., & Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee (2026). Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity. The Journal of Clinical Pharmacology, 66(10). https://doi.org/10.1002/jcph.70264

Vancouver

Maglalang PD, Gonzalez D, Muller WJ, Hornik CD, Goldstein SL, Rathore M, et al. Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity. The Journal of Clinical Pharmacology. 2026;66(10). doi:10.1002/jcph.70264

BibTeX
@article{Maglalang2026,
  author = {Maglalang, Patricia D and Gonzalez, Daniel and Muller, William J and Hornik, Chi D and Goldstein, Stuart L and Rathore, Mobeen and Ford, Jennifer L and Balevic, Stephen J and Sinha, Jaydeep and Edginton, Andrea and Greenberg, Rachel G and Benjamin, Daniel K and Chen, Jia-Yuh and Zimmerman, Kanecia O and Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee, Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee},
  title = {Physiologically Based Pharmacokinetic Modeling to Characterize the Disposition of Topiramate in Children with and without Obesity},
  journal = {The Journal of Clinical Pharmacology},
  year = {2026},
  volume = {66},
  number = {10},
  doi = {10.1002/jcph.70264}
}
Kostenlos starten →